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Abstract 
Background. Allyphenyline, a novel α2-adrenoceptor (AR) ligand has been shown to 
selectively activate α2C-adrenoceptors (AR) and 5HT1A receptors, but also to behave as a 
neutral antagonist of α2A-ARs. We exploited this unique pharmacological profile to analyze 
the role of α2C-ARs and 5HT1A receptors in the regulation of gastric mucosal integrity and 
gastrointestinal motility. Methods. Gastric injury was induced by acidified ethanol in Wistar 
rats. Mucosal catalase and superoxide dismutase levels were measured by assay kits. The 
effect of allyphenyline on electrical field stimulation (EFS)-induced fundic and colonic 
contractions was determined in C57BL/6 mice. Results. Intracerebroventricularly injected 
allyphenyline (3 and 15 nmol/rat) dose-dependently inhibited the development of mucosal 
damage, which was antagonized by both ARC 239 (α2B/C-AR and 5HT1A receptor antagonist), 
(S)-WAY 100135 (selective 5HT1A receptor antagonist) and JP-1302 (selective α2C-AR 
antagonist). This protection was accompanied by significant elevation of mucosal catalase and 
superoxide dismutase levels. Allyphenyline (10-9 – 10-5 M) also inhibited EFS-induced fundic 
contractions, which was antagonized by ARC 239 and (S)-WAY 100135, but not by JP 1302. 
Similar inhibition was observed in the colon, however, in this case only ARC 239 reduced this 
effect, while neither selective inhibition of α2C-ARs and 5HT1A receptors, nor genetic deletion 
of α2A- and α2B-ARs influenced it. Conclusions. Activation of both central α2C-ARs and 
5HT1A receptors contributes to the gastroprotective action of allyphenyline in rats. Its 
inhibitory effect on fundic contractions is mediated by 5HT1A receptors, but neither α2-ARs, 
nor 5HT1A receptors take part in its inhibitory effect on colonic contractility in mice. 
 
Keywords: allyphenyline, gastroprotection, fundic relaxation, colonic motility, alpha2C 
adrenergic receptor, 5HT1A receptor 
1. Introduction 
α2-adrenoceptors (α2-ARs) belong to the superfamily of G-protein coupled receptors 
and consist of three different molecular subtypes (α2A, α2B and α2C) [1], which are widely 
distributed in the central nervous system (CNS) and in peripheral tissues and possess distinct 
functional and pharmacological properties (for reviews see [2-4]). The synthesis of subtype 
selective ligands and generation of genetically engineered mice have allowed significant 
advances in our understanding of the role of each subtype. Several studies demonstrated that 
most of the classical effects of α2-AR agonists, such as hypotension, bradycardia or sedation 
are mediated entirely or predominantly by the α2A-subtype [2, 4]. 
Since the pioneering work of Paton and Vizi [5], who reported the localization of 
presynaptic α2-ARs on cholinergic myenteric nerves and their inhibitory action on the release 
of acetylcholine, a vast amount of data has been accumulated on the role of these receptors in 
the gastrointestinal (GI) tract as well. Besides cholinergic neurons α2-ARs are also localized 
on extrinsic noradrenergic neurones (autoreceptors), as well as on enterocytes and smooth 
muscles, and their activation results in various effects, such as inhibition of GI motility, 
secretion and visceral sensation, and increased intestinal absorption of water and electrolytes 
[6, 7]. Moreover, there is evidence that α2-ARs localized in the CNS are also involved in the 
inhibition of GI motility and secretion [8, 9, 10]. Due to all these actions α2-ARs are 
considered attractive therapeutic targets for the treatment of a wide range of GI disorders, 
including functional dyspepsia, irritable bowel syndrome and inflammatory bowel diseases [7, 
11]. However, most GI effects are mediated mainly by the α2A-AR subtype [4, 7, 12], and 
pharmacologic modulation of this subtype in the above mentioned diseases by non-selective 
or subtype-selective α2-AR ligands may result in numerous undesirable side effects outside 
the GI tract (see above). 
In the last two decades our research group demonstrated that α2-AR agonists induce a 
potent defensive effect in the stomach and reduce the extent of mucosal injury in both acid-
dependent (indomethacin) and independent (ethanol) ulcer models [12-17]. More importantly, 
our results clearly showed that this protective effect is mediated by α2B- and α2C-ARs 
localized in the brain, most probably in the dorsal vagal complex, and α2A-ARs do not have 
any significant role in it [12, 14, 17]. Accordingly, we proposed that selective α2B/C-AR 
agonists may represent a novel group of gastroprotective agents, which are devoid of several 
side effects mediated by the α2A-AR subtype, such as hypotension, bradycardia or sedation 
[17]. However, although the site of gastroprotective action is likely to be central, it should be 
considered that α2B-ARs are located also postsynaptically on vessels [18, 19] and appear to be 
involved in the vasoconstrictor response to α2-AR agonists [20] and in salt-induced 
hypertension [21]. Consequently, selective α2C-AR stimulants are likely to be even more 
favourable and safer potential therapeutic agents against gastric mucosal injury than the 
mixed α2B/C-AR agonists, since they are devoid of adverse effects due to activation of both 
α2A- and α2B-ARs. 
In the recent years allyphenyline, a novel α2-AR ligand endowed with peculiar 
pharmacological profile has been synthetized and characterized [22-24]. Among the three α2-
AR subtypes allyphenyline behaves as an agonist only at the α2C-AR subtype, while it does 
not bind to α2B-ARs and behaves as a neutral antagonist at the α2A-AR subtype in vitro [22]. 
In line with it, allyphenyline enhanced morphine analgesia and attenuated morphine 
withdrawal symptoms in vivo (due to its α2C-AR agonist property), but it was devoid of any 
sedative effect (due to its α2A-AR-antagonism) [23, 24]. 
Regarding other receptors, allyphenyline also binds to and activate 5HT1A receptors 
[25], and dual activation of α2C-ARs and 5HT1A receptors by this compound elicited 
antidepressant- and anxiolytic-like effects in rodents [25, 26]. 5HT1A receptors have been 
implicated in numerous GI processes, such as gastric mucosal protection [27, 28], inhibition 
of cholinergic gastric contractions [29, 30], as well as modulation of colonic motility [31]. It 
should be emphasized that ulcer disease is often accompanied by increased gastric motility 
[32], consequently inhibition of GI motility may contribute to the therapeutic effect of an anti-
ulcer agent. 
Based on the receptorial actions we hypothesized that allyphenyline may induce 
gastroprotective action (due to dual activation of α2C-ARs and 5HT1A receptors), and may also 
inhibit GI motility, in spite of the lack of α2A-AR activation (due to 5HT1A receptor agonism). 
Our results confirmed our expectations and demonstrated that 1) allyphenyline 
potently inhibits the development of ethanol-induced mucosal damage, and central α2C-ARs 
and 5HT1A receptors are both involved in this action, 2) allyphenyline concentration-
dependently suppresses cholinergic contractions in the stomach, which effect is – at least 
partly – mediated by 5HT1A receptors, but not by α2C-ARs, and 3) allyphenyline also 
suppresses cholinergic contractions in the colon, but this effect does not depend on the 
activation of 5HT1A receptors and α2-ARs. Hence, the unique receptorial profile makes 
allyphenyline particularly attractive for the treatment of various GI disorders, such as peptic 
ulcers, functional dyspepsia (FD) or irritable bowel syndrome (IBS), because both mucosal 
protection, fundic relaxation and inhibition of colonic motility can be achieved without 
inducing α2A- and α2B-AR-mediated unwanted side effects. 
2. Methods 
2.1. Synthesis of allyphenyline 
Allyphenyline (2-(1-(2-allylphenoxy)ethyl)-4,5-dihydro-1H-imidazole) [22] was 
obtained from 2-(2-allylphenoxy)propanenitrile [33] by treatment with sodium methoxide in 
methanol and subsequent condensation with ethylenediamine, as reported in Fig. 1. 
2.2. Animals 
For in vivo analysis of gastric mucosal defensive processes male Wistar rats weighing 
150-170 g (Semmelweis University) were used [15], while for ex vivo analysis of gastric and 
colonic contractility C57BL/6 mice from both sexes (20-25 g, National Institute of Oncology) 
[34]. α2A- and α2B-AR knockout mice (with the same C57BL/6 genetic background) were the 
generous gift of Prof. L. Hein (University of Freiburg, Germany). The generation of these 
mouse lines has been described previously in detail [20, 35]. Genotypes were confirmed by 
subtype-specific polymerase chain reactions (with a TProfessional Basic Thermocycler, 
Biometra) performed with genomic DNA isolated from tail biopsies as described previously 
[36]. Animals were housed in a temperature- and humidity-controlled room at a 12-h 
light/dark cycle under conditions of animal housing and experimentation according to ethical 
guidelines issued by the Ethical Board of Semmelweis University, based on EC Directive 
86/609/EEC. 
All procedures conformed to the European Convention for the protection of vertebrate 
animals used for experimental and other scientific purposes, and all efforts were made to 
minimize the suffering of animals. The experiments were approved by the National Scientific 
Ethical Committee on Animal Experimentation and permitted by the government (Food Chain 
Safety and Animal Health Directorate of the Central Agricultural Office (PEI/001/1493-
4/2015). 
2.3. In vivo analysis of gastric mucosal protective processes 
Before the experiments rats were deprived of food for 24 h with free access to tap 
water. Gastric mucosal lesions were induced by acidified ethanol (98 ml absolute ethanol + 2 
ml concentrated HCl), which was given intragastrically in a volume of 0.5 ml/rat by an oral 
gavage using a stainless steel cannula. All test compounds were injected into the lateral brain 
ventricle (intracerebroventricularly, i.c.v.) 10 min before the ethanol challenge in a volume of 
10 μl, as described previously [15]. 60 min after the injection of ethanol the animals were 
sacrificed, the stomachs were excised and opened along the greater curvature. The flattened 
stomachs were photographed and pixel numbers of the damaged and total mucosal areas were 
determined using a free photo editing software. The percentage of the damaged mucosal area 
in each stomach was calculated as follows: [(pixel number of ulcerated mucosa / pixel number 
of total mucosal area) *100]. After the stomachs were photographed, gastric mucosa was 
separated on a cooled plate, shock-frozen in liquid nitrogen and stored at –80°C until further 
assayed. 
Study design. In four consecutive experiments a total of 80 rats were randomly divided 
into 16 groups (4 groups/experiment, 5 rats/group). In the first experiment rats received water 
per os and vehicle i.c.v. (absolute control group), acidified ethanol per os and vehicle i.c.v. 
(ethanol control group), or acidified ethanol per os and allyphenyline i.c.v. at 2 different doses 
(3 and 15 nmol). In the three other experiments rats received acidified ethanol per os and 
vehicle, allyphenyline (15 nmol), an α2-AR and/or 5HT1A receptor antagonist, or the 
combination of allyphenyline and the respective antagonist i.c.v. The applied doses of drugs 
were selected based partly on our preliminary results, partly on the literature data [16, 17, 25, 
26]. 
2.4. Catalase assay 
Catalase (CAT) enzyme activity was measured by using an assay kit (Cayman Europe, 
Tallinn, Estonia) according to the manufacturer's instructions. This kit utilizes the peroxidatic 
function of CAT for determination of enzyme activity. The method is based on the reaction of 
the enzyme with methanol in the presence of an optimal concentration of H2O2. The 
formaldehyde produced was measured spectrophotometrically with 4-amino-3-hydrazino-5-
mercapto-1,2,4-triazole as the chromogen. One unit of CAT was defined as the amount of 
enzyme that causes the formation of 1 nmol of formaldehyde per minute at 25◦ C. CAT 
activity was expressed in nmol/min/mg tissue. 
2.5. Superoxide dismutase assay 
Superoxide dismutase (SOD) activity was measured by using an assay kit (Cayman 
Europe, Tallinn, Estonia) according to the manufacturer's instructions. This kit utilizes a 
tetrazolium salt for the detection of superoxide radicals generated by xanthine oxidase and 
hypoxanthine, and measures the activity of all three types of SOD (Cu/Zn, Mn and Fe-SOD). 
One unit of SOD was defined as the amount of enzyme needed to exhibit 50% dismutation of 
the superoxide radical (O2˙−). SOD activity was expressed in unit/mg tissue. 
2.6. Ex vivo analysis of fundic contractility 
The preparation of gastric fundus strips was performed as described previously [34]. 
Briefly, mice were killed by cervical dislocation, the entire stomach was removed and placed 
in Petri dish containing Krebs solution and aerated with carbogen (mixture of 95% O2 and 5% 
CO2). The fundal part was separated from the pyloric part of each stomach and 2-2.5 cm long 
fundus strips were prepared by transverse cuts on each side of the strip parallel to the 
longitudinal muscle. From each stomach only one strip was prepared. 
The isolated gastric fundus strips were suspended between upper (ring) and lower 
(straight) electrodes in organ baths of 5 ml volume containing Krebs solution aerated with 
carbogen at 37◦C. Krebs solution has the following composition (mM/L): NaCl, 118.0; 
NaHCO3, 25.0; KCl, 4.7; KH2PO4, 1.2; glucose, 11.0; CaCl2, 2.5; MgSO4, 1.2. The upper end 
of the strip was attached by thread to a transducer, connected to a computer through an 
amplifier. The resting tension was adjusted to 0.5 g. To induce contraction of gastric fundus 
strip, electrical field stimulation (EFS) was used with the following stimulation parameters: 
pairs (200 ms pulse distance) of rectangular impulses (1 ms pulse width, 25 shocks, 9 V/cm 
i.e. supramaximal intensity of 5 Hz) were repeated in 60 seconds. Each impulse induced a fast 
contractile response, followed by a slower relaxation response, whose amplitudes were 
constant over a period of 60 min (pilot experiments). The contractions were abolished by 
atropine (1 µM), indicating the predominant role of the cholinergic system in the contractile 
response, while the relaxations were inhibited by Nω-Nitro-L-arginine (L-NNA, 10 µM), 
indicating the activation of nitrergic pathways. 
After setting up, strips were allowed to equilibrate for 30-45 min before adding the 
first concentration of allyphenyline or clonidine (non-selective α2-AR agonist, used as a 
reference compound). A period of 5 min was allowed to elapse between concentration 
increment. Cumulative concentration-response curves were constructed for both agonists. 
When the effects of the antagonists (ARC 239, (S)-WAY 100135 and JP-1302) on the 
inhibitory effect of allyphenyline were assessed, the antagonists (1 µM) were added to the 
organ bath 20 min prior the first concentration of allyphenyline. The antagonists in this 
concentration were effective and selective [34, 37 - 39]. Drugs were given in volumes less 
than 1% of total bath volume. 
The 50% effective concentrations (EC50) and maximal inhibitory effect (Emax) of 
agonists were calculated from the nonlinear regression of individual sigmoid concentration 
response curves. The average of 5 peaks of contractions before adding the agonists was taken 
as 100% (control). The inhibitory effect of the agonists (the mean of 5 peaks) was expressed 
as a percentage to the control contractions. 
2.7. Ex vivo analysis of colonic contractility 
Besides the stomach the most distal (~ 2 cm) segment of the colon was also removed 
from the same mouse. The same steps were followed as in the preceding case, but based on 
preliminary studies stimulation parameters were modified, and single rectangular impulses (1 
ms pulse width, 1 shock, 9 V/cm i.e. supramaximal intensity of 5 Hz) were repeated in 30 
seconds. These impulses induced a fast, slight relaxation response followed by a contractile 
response, with constant amplitudes over a period of 60 min, and were abolished by L-NNA 
(10 µM) and atropine (1 µM), respectively. 
2.8. Chemical compounds 
Clonidine hydrochloride (non-selective α2-AR agonist, PubChem CID 2803) and JP-
1302 trihydrochloride hydrate (selective α2C-AR antagonist, PubChem CID 540335) were 
purchased from Sigma-Aldrich (St. Louis, USA), while (S)-WAY 100135 dihydrochloride 
(selective 5HT1A receptor antagonist, PubChem CID 6604840) and ARC 239 dihydrochloride 
(α2B/C-AR and 5HT1A receptor antagonist, PubChem CID 609483) were obtained from Tocris 
Bioscience (Bristol, UK). Allyphenyline (PubChem CID 24906198) was synthetized as 
described above. All drugs were dissolved in saline (in vivo) or in distilled water (ex vivo). 
For controls the respective vehicles were used. 
2.9. Statistical analysis 
Data are expressed as means ± S.E.M. Statistical analysis of the data was performed 
either with Student’s t-test (two treatment groups), or with one-way ANOVA followed by 
Newman-Keuls post-hoc test, or (in the case of comparing concentration-response curves) by 
two-way repeated measures ANOVA followed by Holm-Sidak post-hoc test. A probability of 
p<0.05 was considered statistically significant. 
3. Results 
3.1. The effect of allyphenyline on ethanol-induced mucosal damage 
Oral administration of acidified ethanol induced multiple longitudinal hemorrhagic 
lesions on the gastric mucosa (damaged mucosal area: 9.3 ± 1.9 %, n=20, Fig. 2). I.c.v. 
injection of allyphenyline (3 and 15 nmol/rat) 10 min before the ethanol challenge dose-
dependently reduced the development of mucosal lesions, at the higher dose it induced almost 
complete inhibition (damaged areas: 1.4 ± 0.5 % and 0.2 ± 0.1 %, respectively, n=5, p<0.01, 
which correspond to 21.7 % and 4 % of the damaged area in the respective ethanol control 
group, Fig. 2). 
As Fig. 3 shows, the formation of mucosal lesions in the ethanol-treated animals was 
associated with significantly reduced SOD activity in the gastric mucosa (0.47 ± 0.04 vs 0.32 
± 0.02 unit/mg tissue, n=5, p<0.001), while this reduction was completely prevented by 
allyphenyline (0.53 ± 0.03 unit/mg tissue, n=5, p<0.001), indicating that it counteracted the 
pro-oxidant effect of ethanol. Similarly, the mucosal CAT activity was significantly higher in 
the allyphenyline+ethanol-treated group than in the ethanol control group (vehicle+ethanol: 
0.27 ± 0.03, allyphenyline+ethanol: 0.56 ± 0.15 nmol/min/mg tissue, n=5-10, p<0.05). 
3.2. Analysing the involvement of α2C-ARs and 5HT1A receptors in the gastroprotective 
effect of allyphenyline 
The mucosal protective action of i.c.v. injected allyphenyline was completely inhibited 
by ARC 239 (50 nmol/rat i.c.v., Fig. 2). Although this compound is widely used as an α2B/C-
AR antagonist, there is evidence that it also binds to 5HT1A receptors with nanomolar affinity 
[37]. Hence, the inhibitory action of ARC 239 indicates only that at least one of these 
receptors is involved in mediating the effect of allyphenyline. For further analysis we used 
(S)-WAY 100135 (50 nmol/rat) and JP 1302 (56 nmol/rat), selective antagonists of 5HT1A 
receptors and α2C-ARs, respectively [38, 39]. As Fig. 2 shows, both compounds inhibited the 
effect of allyphenyline, suggesting that both α2C-ARs and 5HT1A receptors contribute to the 
gastroprotection. When given alone, none of the antagonists influenced significantly the 
development of ethanol-induced lesions. 
3.3. The effect of allyphenyline on EFS-induced fundic and colonic contractions 
As Fig. 4 demonstrates, allyphenyline inhibited EFS-evoked cholinergic contractions 
in both fundus and colon in a concentration-dependent fashion. While in the stomach 
allyphenyline was one order of magnitude less potent than clonidine, a prototypical non-
selective α2-AR agonist (EC50 values are 240.8 ± 71.6 and 20.8 ± 6.2 nM, respectively), in the 
colon they had comparable potencies and efficacies (Table 1). Fig. 4B and 4D show 
representative tracings illustrating the effect of allyphenyline on EFS-induced fundic and 
colonic cholinergic contractions. In contrast to the EFS-evoked contractile response, 
allyphenyline did not influence the nitrergic relaxation (not shown). 
3.4. Analysing the involvement of α2C-ARs and 5HT1A receptors in the allyphenyline-
evoked inhibition of fundic and colonic contractions 
ARC 239 (1 µM) did not influence the amplitude of EFS-induced twitch contractions 
in the stomach or in the colon per se, but significantly reduced the inhibitory effect of 
allyphenyline in both organs (Figs. 5A and 6A). However, in the stomach it shifted the 
concentration-response curve of allyphenyline rightward, and increased its EC50 value without 
significantly altering its Emax, while in the colon it reduced allyphenyline’s Emax, without 
significantly changing its EC50 value (Table 1). These results suggest that the interactions 
between allyphenyline and ARC 239 in the two organs might involve different mechanisms of 
action. (S)-WAY 100135 (1 µM), similarly to ARC 239, did not alter EFS-induced fundic and 
colonic contractions alone, but significantly reduced the effect of allyphenyline in the 
stomach. On the other hand, it failed to modify that in the colon (Figs. 5B and 6B, Table 2). In 
contrast to the other two antagonists, JP 1302 (1 µM) affected the effect of allyphenyline 
neither in the stomach, nor in the colon (Figs. 5C and 6C, Table 1). 
These data indicate that 5HT1A receptors are involved in mediating the inhibitory 
effect of allyphenyline on fundic motility, but neither these receptors, nor α2C-ARs take part in 
the inhibition of EFS-induced contractions in the colon. Though previous in vitro and in vivo 
studies did not indicate the involvement of α2A- and α2B-ARs in the action of allyphenyline 
[22-24], we also wanted to exclude the participation of these receptors in the inhibitory effect 
of allyphenyline on colonic motility. Therefore we compared its effect in wild type, α2A- and 
α2B-AR KO mice. However, as Figs. 6D and 6E demonstrate, the concentration-response 
curves were the same in all lines, which rules out the involvement of these α2-AR subtypes in 
the effect of allyphenyline. 
4. Discussion 
In the present study we aimed to characterize the GI effects of a novel α2C-AR 
agonist/α2A-AR antagonist/5HT1A receptor agonist agent named allyphenyline, in terms of 
gastroprotection and regulation of GI motility. Our data demonstrate that allyphenyline 
possesses powerful gastroprotective action, which is mediated by central α2C-ARs and 5HT1A 
receptors, and inhibits both fundic and colonic contractions evoked by EFS, although 
probably via different, 5HT1A receptor-dependent and indepedent mechanisms, respectively. 
It is well-established, that peptic ulcers develop as a result of impaired balance 
between the aggressive and protective factors of gastroduodenal mucosa [40]. Although 
introduction of antisecretory agents and antibiotic protocols against H. pylori resulted in a 
significant fall of the incidence of peptic ulcers, there is still a clinical need to find novel 
gastroprotective drugs which prevent the development and/or accelerate the healing of 
nonsteroidal anti-inflammatory drug (NSAID)-induced ulcers, H. pylori positive and negative 
gastroduodenal ulcers as well as stress-related ulcers in critically ill patients [41-43]. Since the 
historic article of Andre Robert [44] on „gastric cytoprotection” numerous endogenous and 
exogenous compounds and receptors have been shown to induce and mediate 
gastroprotection, i.e. prevention of ulcer formation without influencing gastric acid secretion 
(recent reviews: [42, 45-49]). 
In the last two decades our group provided mounting evidence for the gastroprotective 
effect of α2-AR agonists. We demonstrated that clonidine and rilmenidine, when given either 
peripherally (per os, subcutaneously) or centrally (i.c.v.), inhibited potently the direct 
necrotizing action of acidified ethanol on gastric mucosa in both rats and mice [12-17]. Our 
results also showed that the site of action is presumably within the CNS [16, 17], where the 
activation of α2B- and α2C-ARs initiates a chain of events resulting in vagally mediated release 
of mucosal protective factors, such as prostaglandins and nitric oxide [13, 16]. Because α2-AR 
agonists are widely used as antihypertensive drugs, as adjuncts to anesthetics and analgesics 
during the perioperative period, or as drugs to treat opiate withdrawal or attention-
deficit/hyperactivity disorder [50], a potential anti-ulcer effect is of high clinical relevance. 
However, non-selective activation of all three α2-AR subtypes in the ulcer therapy would 
result in numerous undesired side effects, mainly mediated by the α2A-AR subtype 
(hypotension, bradycardia, sedation), but partly also by the α2B-AR subtype (vasoconstriction) 
[2, 4, 19]. Hence, selective stimulation of α2C-ARs would provide a safer approach to treat 
upper GI mucosal lesions. 
Besides α2-ARs also 5HT1A receptors have been implicated in the regulation of gastric 
mucosal integrity. Various selective 5HT1A receptor agonists, such as buspiron, 8-OH-DPAT, 
lesopitron (E-4424), E-4414 or E-4804, given either orally or i.p., were shown to inhibit 
gastric acid and pepsin secretion, to increase gastric adherent mucus levels and to reduce 
mucosal injury in both acid-dependent (cold-restraint stress, indomethacin, conditioned fear) 
and independent (ethanol) ulcer models [27, 28, 51-53]. Whether the site of action is within 
the CNS or in the periphery has not been established, but Farre et al. [27] (based on 
unpublished observations) suggested that both central and peripheral effects may contribute to 
the mucosal protection. The possibility of a central component is indirectly supported by 
Hoshino and Sugizaki [54], who reported that destruction of the median raphe nucleus, a 
significant site of central 5-HT cell bodies, was associated with an increased incidence of 
gastric lesions. 
Based on the data described above, we hypothesized that allyphenyline, a novel 
compound synthetized by Gentili et al. [22] possessing a particularly intriguing receptorial 
profile (α2C-AR agonist/α2A-AR antagonist/5HT1A receptor agonist), would exert potent 
gastroprotective action. Our results confirmed this hypothesis and showed that centrally 
injected allyphenyline almost completely inhibited the development of gastric mucosal 
damage induced by ethanol, indicating its ability to recruit protective factors and enhance 
mucosal defense. This effect was inhibited by co-injection with both ARC 239 (α2B/C-AR and 
5HT1A receptor antagonist), (S)-WAY 100135 (selective 5HT1A receptor antagonist) and JP-
1302 (selective α2C-AR antagonist), which suggests that central α2C-ARs and 5HT1A receptors 
contribute equally to the gastroprotective action. It is of note that similar dual receptorial 
action was observed by Del Bello et al. [25], who reported that yohimbine and (S)-WAY 
100135 similarly contrasted the antidepressive-like effect of allyphenyline. 
Although a detailed analysis of the peripheral factors involved in the mucosal 
protection was above the scope of the present study, we addressed the question of whether 
allyphenyline is able to counteract oxidative stress, an important factor in the 
pathomechanism of various experimental ulcers (e.g. NSAID, stress, ethanol) [55-58], as well 
as in H. pylori-associated ulcers [59]. It is well-established that excessive production of 
reactive oxygen species (ROS) and/or their decreased elimination by antioxidant enzymes 
induce cell and tissue damage by promoting lipid peroxidation and increasing the production 
of inflammatory mediators and proinflammatory cytokines [60]. Reduced mucosal 
antioxidative capacity and increased level of lipid peroxidation products (e.g. 
malondialdehyde) correlate well with macroscopic and histological mucosal damage, and 
agents endowed with antioxidant property are able to prevent ROS-mediated cellular damage 
[55-58, 61]. Our results show that allyphenyline significantly increased the mucosal content 
of SOD (which enzyme catalyzes the dismutation of O2˙− into less noxius hydrogen peroxide 
(H2O2)) and CAT (which accelerates the breakdown of H2O2 to water and oxygen) compared 
to the ethanol-treated group, suggesting that the gastroprotective action of allyphenyline – at 
least partly – relies on its ability to enhance the activity of mucosal antioxidant enzymes and 
reduce the damaging effect of ROS. 
Besides inducing gastric mucosal protection allyphenyline also inhibited EFS-induced 
cholinergic contractions in the murine fundus ex vivo. Compared to clonidine, a non-selective 
α2-AR agents, allyphenyline proved to be one order of magnitude less potent. Because among 
the three α2-AR subtypes allyphenyline activates only the α2C-AR subtype [22, 23], which 
does not have any role in the modulation of gastric motility in mice [34], the inhibitory effect 
of allyphenyline may result from its serotonergic property, and not from an interaction with 
α2-ARs. Indeed, we found that (S)-WAY 100135 significantly reduced the inhibitory effect of 
allyphenyline in the stomach, similarly to ARC 239, while JP 1302 had no relevant effect on 
it. These findings indicate the involvement of 5HT1A receptors in the inhibitory response, 
which is in line with previous observations. Namely, presynaptic 5-HT1A receptors were 
shown to mediate the inhibition of transmitter release from cholinergic nerve endings in the 
guinea pig antrum [29], and various 5HT1A receptor agonists (buspirone, R137696 or 
flesinoxan) were shown to relax the proximal stomach in mice [30, 62], dogs [63] and also in 
humans [64, 65]. In accordance with the literature data [63] we found that nitrergic nerves are 
not involved in the 5-HT1A receptor-mediated fundic relaxation, because allyphenyline did not 
influence the EFS-induced L-NNA-sensitive relaxation response. 
Relaxation of the fundus, either by inhibiting the cholinergic drive or by stimulating 
the activity of inhibitory (nitrergic or VIP-ergic) neurons may result in enhanced gastric 
accommodation [66]. Since impaired gastric accommodation is a hallmark of functional 
dyspepsia (FD) and contributes to a number of dyspeptic symptoms including nausea and 
early satiety, improving gastric accommodation by 5HT1A receptor agonists is a promising 
approach to treat dyspeptic patients [66-68]. Supporting this concept, buspirone and 
tandospirone significantly improved the symptoms of FD patients [69, 70], although in the 
case of tandospirone the beneficial effect was attributed mainly to its anxiolytic property. 
Considering the potent gastroprotective, fundic relaxing and anxiolytic [26] properties of 
allyphenyline we propose that this compound may be a useful tool in the therapy of both 
peptic ulcers and non-ulcer dyspepsia. 
Our results demonstrate that in addition to the fundic relaxation allyphenyline also 
potently inhibits cholinergic contractions in the colon, however, via an unknown mechanism. 
First, neither pharmacologic inhibition of α2C-ARs by JP 1302, nor genetic deletion of α2A- 
and α2B-ARs altered the effect of allyphenyline. These results not only indicate that α2C-ARs 
are not involved in the control of colonic motility, but also confirm the original findings of 
Gentili et al. [22] that allyphenyline does not activate the α2A-AR subtype, which otherwise 
regulates colonic contractility [71]. Second, the effect was not affected by (S)-WAY 100135, 
which rules out the involvement of 5-HT1A receptors. The exact role of these receptors in the 
control of colonic motility is still enigmatic [72], but recent findings suggest that these 
receptors take part in the modulation of colonic migrating motor complex by limiting the 
neurotransmitter output from intrinsic primary afferent neurons (IPANs) to ascending (S Type 
I) interneurons [31]. Our results suggest that 5-HT1A receptors are not involved in the 
inhibition of cholinergic contractions in the murine colon. Interestingly, ARC 239 reduced the 
colonic effect of allyphenyline, which implies that it interferes with the binding of 
allyphenyline to another, yet unidentified molecular target. However, even if the exact 
pharmacodynamic action remains to be established, the modulatory action of allyphenyline in 
the colon may be useful in various conditions with increased motility. It should be noted that 
there is a considerable overlap between FD and IBS patients [73, 74], and allyphenyline may 
have significant impact on most symptoms in these patients. 
In summary, we demonstrated herein that allyphenyline possesses powerful 
gastroprotective action, which is mediated by central α2C-ARs and 5HT1A receptors, and 
inhibits both fundic and colonic contractions evoked by EFS, via 5HT1A receptor-dependent 
and indepedent mechanisms, respectively. These results 1) confirm the role of central α2C-
ARs in the regulation of gastric mucosal integrity and provide the first evidence for the role of 
central 5HT1A receptors in it, 2) confirm the presence and inhibitory effect of presynaptic 
5HT1A receptors on cholinergic motor neurons at the level of stomach, and 3) from a clinical 
aspect suggest that allyphenyline may be a particularly useful tool in the treatment of various 
GI disorders, such as peptic ulcers, functional dyspepsia or irritable bowel syndrome. 
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Figure Legends 
Fig. 1.  
Synthesis of allyphenyline (50% yield). The free base was transformed into the oxalate 
salt; which was recrystallized from 2-PrOH: mp 154-155 °C. 1H NMR (DMSO): δ 1.53 (d, 3, 
CH3), 3.42 (m, 2, CH2CH), 3.88 (s, 4, NCH2CH2N), 5.06 (dd, 2, CH=CH2), 5.40 (q, 1, OCH), 
5.95 (m, 1, CH=CH2), 6.92-7.26 (m, 4, ArH), 7.81 (br s, 1, NH, exchangeable with D2O). 
Anal. Calcd for C14H18N2O H2C2O4: C, 56.80; H, 6.55; N, 8.28. Found: C, 56.69; H, 6.71; N, 
8.13. 
Fig. 2. 
Panel A. The effect of allyphenyline (ALL, 3 and 15 nmol/rat) on ethanol (ETH)-
induced gastric mucosal injury in the absence and presence of ARC 239 (ARC, 50 nmol/rat), 
(S)-WAY 100135 (WAY, 50 nmol/rat) and JP 1302 (JP, 56 nmol/rat). Allyphenyline was 
injected intracerebroventricularly (i.c.v.) either alone or together with the respective 
antagonists 10 min before the ethanol challenge. In order to compare the inhibitory effects of 
the antagonists used in three different experiments, the damaged mucosal area of each 
stomach was normalized to the mean value of the respective ethanol control group (100 %). 
Each column represents mean (± S.E.M.) of 5 rats. **P<0.01 compared with ethanol-treated 
group (column 2); #P<0.05, ##P<0.01 compared with allyphenyline 15 nmol-treated group 
(column 4) (ANOVA, Newman-Keuls post hoc test). 
Panel B. Representative macroscopic pictures demonstrating the mucosal protective 
effect of allyphenyline (ALL) and the inhibitory effect of ARC 239 (ARC), (S)-WAY 100135 
(WAY) and JP 1302 (JP) on it. The dark, livid areas represent the hemorrhagic ulcerous part 
of the mucosa. 
Fig. 3. 
The effect of ethanol (ETH) and allyphenyline (ALL) on the mucosal catalase (CAT, 
panel A) and superoxide dismutase (SOD, panel B) activity. Allyphenyline (15 nmol) was 
injected intracerebroventricularly (i.c.v.) 10 min before the ethanol challenge. ). Each column 
represents mean (± S.E.M.) of 5-10 rats. *P<0.05 compared with ethanol-treated group 
(column 2) (ANOVA, Newman-Keuls post hoc test). 
Fig. 4. 
The inhibitory effect of allyphenyline (ALL) and clonidine (CLO) on cholinergic 
fundic (panel A) and colonic (panel C) contractions induced by EFS in C57BL/6 mice. The 
numbers in brackets indicate the number of experiments. Both agonists were added 
cumulatively into the organ bath at increasing concentration every 5 min. Each concentration 
response curve represents the mean ± S.E.M. values of inhibition. 
Panels B and D: Representative tracings illustrating the inhibitory effect of 
allyphenyline (ALL, 10-9 – 10-5 M) on the EFS-induced fundic and colonic contractions in 
C57BL/6 mice. 
Fig. 5. 
The antagonistic effect of ARC 239 (ARC, 10-6 M, panel A), (S)-WAY 100135 
(WAY, 10-6 M, panel B) and JP 1302 (JP, 10-6 M, panel C) on the inhibitory effect of 
allyphenyline (ALL, 10-9 – 10-5 M) on EFS-induced fundic contractions. Each circle 
represents mean ± S.E.M values of inhibition (empty circles: agonist alone, filled circles: 
agonist + antagonist), numbers in brackets indicate the number of experiments. #P<0.05 (two-
way repeated measures ANOVA, Holm-Sidak post-hoc test). 
Fig. 6. 
Panels A-C: The antagonistic effect of ARC 239 (ARC, 10-6 M, panel A), (S)-WAY 
100135 (WAY, 10-6 M, panel B) and JP 1302 (JP, 10-6 M, panel C) on the inhibitory effect of 
allyphenyline (ALL, 10-9 – 10-5 M) on EFS-induced colonic contractions. Each circle 
represents mean ± S.E.M values of inhibition (empty circles: agonist alone, filled circles: 
agonist + antagonist), numbers in brackets indicate the number of experiments. #P<0.05 (two-
way repeated measures ANOVA, Holm-Sidak post-hoc test). 
Panels D and E: The inhibitory effect of allyphenyline (ALL) on EFS-induced colonic 
contractions in wild type and α2A- and α2B-adrenoceptor deficient C57BL/6 mice. Each circle 
represents mean ± S.E.M values of inhibition (empty circles: wild type mice, filled circles: 
respective knock out strain), numbers in brackets indicate the number of experiments. 
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